Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy

Figure 1

Enrichment and summary plots of the immune-related signatures in TCGA. Enrichment plots of (a) CD8+ cell signature, (b) dendritic cell signature, and (c) Th1 signature in TCGA pooled cohort, all cell signatures of the PDL2-high group were mostly enriched. (d, e) Summary plots of cell signatures with enrichment NES and values in each tumor type, except for the Th1 signature enrichment in the PDL2-low group of THYM, all results are consistent with the results of TCGA pooled cohort. (g–i) Enrichment plots with IFN-γ signatures in TCGA pooled cohort, all IFN-γ signatures were enriched in the PDL2-high group. (j–l) Summary plots of IFN-γ signatures with enrichment NES and value in each tumor type, all IFN-γ signatures were enriched in the PDL2-high group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)